Creation of a quality of life instrument for nonmelanoma skin cancer patients

Laryngoscope

Volumn 115, Issue 7, 2005, Pages 1178-1185

  Rhee, John S ^a   Matthews, B Alex ^a   Neuburg, Marcy ^a   Burzynski, Mary ^a   Nattinger, Ann B ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Basal cell cancer; Quality of life; Skin cancer; Squamous cell cancer

Indexed keywords

ADULT; AGED; ARTICLE; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; RELIABILITY; SKIN CANCER;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SKIN NEOPLASMS;

EID: 21844462353     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MLG.0000166177.98414.5E     Document Type: Article

References (33)

1. Santmyire BR, Feldman SR, Fleischer AB Jr. Lifestyle high-risk behaviors and demographics may predict the level of participation in sun-protection behaviors and skin cancer primary prevention in the United States: results of the 1998 National Health Interview Survey. Cancer 2001;92: 1315-1324.
2. Miller DL, Weinstock MA. Nonmelanoma skin cancer in the United States: incidence. J Am Acad Dermatol 1994;30: 774-778.
3. Davis RE, Spencer JM. Basal and squamous cell cancer of the facial skin. Curr Opin Otolaryngol Head Neck Surg 1997; 5:86-92.
4. Gallagher RP, Ma B, McLean DI, et al. Trends in basal cell carcinoma, squamous cell carcinoma, and melanoma of the skin from 1973 through 1987. J Am Acad Dermatol 1990; 23:413-421.
5. Weinstock MA. Nonmelanoma skin cancer mortality in the United States, 1969 through 1988. Arch Dermatol 1993; 129:1286-1290.
6. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol 2000;136:1524-1530.
7. Schreiber MM, Moon TE, Fox SH, Davidson J. The risk of developing subsequent nonmelanoma skin cancers. J Am Acad Dermatol 1990;23:1114-1118.
8. Levi F, La Vecchia C, Te VC, et al. Incidence of invasive cancers following basal cell skin cancer. Am J Epidemiol 1998;147:722-726.
9. Marghoob AA, Slade J, Salopek TG, et al. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications. Cancer 1995;75:707-714.
10. Lindelof B, Sigurgeirsson B, Wallberg P, Eklund G. Occurrence of other malignancies in 1973 patients with basal cell carcinoma. J Am Acad Dermatol 1991;25:245-248.
11. Green AC, O'Rourke MG. Cutaneous malignant melanoma in association with other skin cancers. J NaU Cancer Inst 1985;74:977-980.
12. Holfeld KI, Hogan DJ, Eldemire M, Lane PR. A psychosocial assessment of patients with basal cell carcinoma. J Dermatol Surg Oncol 1990;16:750-753.
13. Cassileth BR, Lusk EJ, Tenaglia AN. A psychological comparison of patients with malignant melanoma and other dermatologic disorders. J Am Acad Dermatol 1982;7: 742-746.
14. Cassileth BR, Lusk EJ, Tenaglia AN. Patients' perceptions of the cosmetic impact of melanoma resection. Plast Reconstr Surg 1983;71:73-75.
15. Blackford S, Roberts D, Salek MS, Finlay A. Basal cell carcinomas cause little handicap. Qual Life Res 1996;5: 191-194.
16. Sigurdardottir V, Bolund C, Brandberg Y, Sullivan M. The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique. Qual Life Res 1993;2:193-203.
17. Trask PC, Paterson AG, Hayasaka S, et al. Psychosocial characteristics of individuals with non-stage IV melanoma. J Clin Oncol 2001;19:2844-2850.
18. Derogatis LR, Morrow GR, Fetting J, et al. The prevalence of psychiatric disorders among cancer patients. JAMA 1983; 249:751-757.
19. Zabora J, BrintzenhofeSzoc K, Curbow B, et al. The prevalence of psychological distress by cancer site. Psychooncology 2001;10:19-28.
20. Katz MR, Irish JC, Devins GM, et al. Psychosocial adjustment in head and neck cancer: The impact of disfigurement, gender and social support. Head Neck 2003;25: 103-112.
21. Mallon E, Newton JN, Klassen A, et al. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol 1999;140:672-676.
22. Morgan M, McCreedy R, Simpson J, Hay RJ. Dermatology quality of life scales: a measure of the impact of skin diseases. Br J Dermatol 1997;136:202-206.
23. Rhee JS, Loberiza FR, Matthews BA, et al. Quality of life assessment in nonmelanoma cervicofacial skin cancer. Laryngoscope 2003;113:215-220.
24. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992;305:160-164.
25. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-579.
26. Rhee JS, Matthews BA, Neuburg M, et al. Quality of life and sun-protective behavior in patients with skin cancer. Arch Otolaryngol Head Neck Surg 2004;130:141-146.
27. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-216.
28. Rhee JS, Matthews BA, Neuburg M, et al. Skin cancer and quality of life: assessment with the Dermatology Life Quality Index. Dermatol Surg 2004;30:525-529.
29. Cella DF. The Manual of The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System. Evanston, IL: Evanston Northwestern Healthcare and Northwestern University, 1997.
30. Ware JE. SF-36 Health Survey Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Center, 1993.
31. Wolf JE Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001;40:709-713.
32. Marmur ES, Schmults CD, Goldberg DJ. A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. Dermatol Surg 2004;30:264-271.
33. Tran H, Chen K, Shumack S. Summary of actinic keratosis studies with imiquimod 5% cream. Br J Dermatol 2003; 149(Suppl 66):37-39.